IVI in the Media

South China Morning Post | The latest coronavirus boosters target Omicron. Are they safe and effective?

Financial News | IVI Director General Jerome Kim: ‘Bill Gates a strong advocate of IVI’

South China Morning Post | Scientists urge people to take second Covid vaccine booster if offered as Omicron continues to spread

Financial Times | Unvaccinated and unprepared, North Korea faces Covid catastrophe

Chosun Ilbo | Jerome Kim, Director General of International Vaccine Institute, named a distinguished professor at Seoul National University

Financial Times | South Korea downgrades Covid to a ‘Class 2’ disease and removes restrictions

South China Morning Post | China was the world’s biggest Covid-19 vaccine exporter. Not any more

The Wall Street Journal | Despite High Covid-19 Case Counts, Asian Nations Learn to Live With the Virus

Barron’s | China Eases Some Covid Testing Rules. It’s a Targeted Approach to Reduce Impact on the Economy.

CNBC | We need to treat Covid as an endemic pathogen and update vaccines: International Vaccine Institute

Financial Times | Beijing digs in to avoid repeating Hong Kong’s Covid mistakes

The Telegraph | Why China and Hong Kong face a devastating new Covid wave

CGTN | Why is China seeing a surge in COVID-19 cases?

Financial Times | Shanghai teeters on the brink of Covid lockdown

ADB Insight | Year of the Vaccine: The Next Steps for Asia and the Pacific to Combat COVID-19

Fortune | Will we all need fourth COVID vaccine booster shots?

The Telegraph | South Korea abandons its successful test and trace system as omicron cases surge

South China Morning Post | Can China’s home-grown mRNA Covid-19 vaccine pass its final tests?

The Guardian | Cuba leads the world in vaccinating children as young as two against Covid

The Telegraph | Vaccine hesitancy among Taiwan’s elderly mars its pandemic performance and prevents reopening

Director General Jerome Kim on The Alex Salmond Show

South China Morning Post | Which vaccines stop Omicron? Search for data moves from labs to real world

CNBC | 2022 will be the ‘year of vaccination,’ says director of vaccine institute

South China Morning Post | As Omicron upends Covid-19 vaccine targets, what will the future look like?

South China Morning Post | Omicron and the Winter Olympics – is China’s zero-Covid strategy up to the challenges?

CBS Mornings | With Omicron on its doorstep, countries in Asia are closing up

National Geographic | Omicron is dodging the immune system—but boosters show promising signs

Khaleej Times | Covid: 96% of people in low-income nations have yet to receive first vaccine dose, says expert

Voice of America | South Korea Showed How to Contain COVID, Now It Will Try to Live With It

China Daily | Experts say countries should remain cautious about reopening borders

South China Morning Post | Next Covid-19 test? Diagnostic blind spots stir visions of bleak midwinter

South China Morning Post | US-China coronavirus vaccine diplomacy heats up but can donations sway allegiances?

The New York Times | How Asia, Once a Vaccination Laggard, Is Revving Up Inoculations

South China Morning Post | Coronavirus: as rich countries turn to big-name booster shots from Pfizer, AstraZeneca, the poor are left with lesser-known rivals like Abdala, Soberana 2

South China Morning Post | Coronavirus: China seeks to develop next-gen vaccines amid trial complications

South China Morning Post | Can China stay ahead as a leading exporter of Covid-19 vaccines?

Maeil Business Newspaper | All music is beautiful in its own way, but Violinist Sang Hee Lee’s music shines a special light

Nature | Six months of COVID vaccines: what 1.7 billion doses have taught scientists

Asian Boss | We Asked Top Vaccine Expert About COVID Vaccine Problems

Bloomberg | Consequences of ‘Huge’ Global Gap in Vaccinations

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

Jerome H. Kim appointed as Director General of IVI

Author
Margaret
Date
2014-09-30 00:00
Views
26885

Jerome H. Kim appointed as Director General of IVI

 

 

 

SEOUL, REPUBLIC OF KOREA – The International Vaccine Institute (IVI), a Seoul-based non-profit international organization devoted to research in vaccine development and delivery for the developing world, announced the appointment of Jerome H. Kim, M.D., as the organization’s Director General, effective early 2015.

 

“Jerome’s scientific knowledge, technical expertise, and organizational and leadership skills, make him an ideal fit for the position,” said Prof. Adel A. Mahmoud, Chair of IVI’s Board of Trustees. “With his distinguished track record in vaccine research & development and passionate commitment to vaccines, he will bring strong scientific leadership and management of a dynamic international organization.”

 

“I am honored by the opportunity to join IVI, and I look forward to working with the IVI team, partners, and donors,” said Dr. Kim, “IVI is a very unique organization. Its breadth in vaccinology spans research & development, epidemiology, technology transfer, policy and access. Together, we will improve the health and wellbeing of the world’s poorest populations through fulfilling IVI’s mission – to discover, develop, and deliver safe, effective and affordable vaccines for developing nations.”

 

A medical doctor by training and a colonel in the United States Army Medical Corps, Dr. Kim is a recognized leader in HIV research and HIV vaccine development. He was named one of “The 50 Most Influential People in Vaccines” in 2014 by the vaccine industry organization Vaccine Nation. Dr. Kim was the Principal Deputy and Chief of the Laboratory of Molecular Virology and Pathogenesis at the U.S. Military HIV Research Program (MHRP) and the U.S. Army's Project Manager for the HIV Vaccines and Advanced Concepts Evaluation and Staging. 

 

He was the U.S. Army lead for the Phase III HIV vaccine trial (RV144), which was the first to show that an HIV vaccine could protect against infection, as well as subsequent studies that identified laboratory correlates and HIV sequence changes associated with vaccination. His research interests include HIV molecular epidemiology, host genetics, and HIV vaccine development.  He has authored over 140 publications.

Dr. Kim is a Professor of Medicine at the Uniformed Services University of the Health Sciences and is a Fellow of the American College of Physicians and the Infectious Diseases Society of America. He received his M.D. from the Yale University School of Medicine, and completed his training in Internal Medicine and fellowship in Infectious Diseases at Duke University Medical Center.

 

“As IVI’s host country and donor, the Republic of Korea is pleased with the appointment of Dr. Kim,” said Dr. Young-Soon Kang, Director General of the International Cooperation Bureau, South Korea’s Ministry of Education, “Dr. Kim is a well-respected and internationally renowned scientist and leader. Under his leadership, IVI is well-positioned to move to the next level, not only in research but also as an organization.”

 

“IVI has been an important long-term partner and grantee of the Bill & Melinda Gates Foundation,” added Dr. Anita Zaidi, Director of Enteric and Diarrheal Diseases at the Bill & Melinda Gates Foundation, “Therefore we are delighted that Dr. Jerome Kim will be the next Director General of IVI.  We look forward to the greater contributions that IVI will make in developing and deploying vaccines for underserved populations under his leadership.”

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.

 

 

Media Contact:

 

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)     

Mobile: +82-11-9773-6071

Email: tkbyun@ivi.int